Saccomanno B, et al. - Authors examined 62 children to estimate the predictors of therapeutic response to the interleukin (IL)-1 inhibitor anakinra in kids with systemic-onset juvenile idiopathic arthritis (sJIA). They observed that 39% of cases met the criteria for complete clinical response (CCR) at 1 year, whereas 61% did not. They recognized independent relationships with achievement of CCR for shorter disease duration, lower active joint count, higher ferritin level, and greater activity of systemic manifestations. They found 0.83, the area under the curve of the model. They delineated the clinical profile of subjects with sJIA who were more likely to benefit from IL-1 blockade.